A novel mRNA decay inhibitor abolishes pathophysiological cellular transition

Daisuke Kami, Toshimasa Ishizaki, Toshihiko Taya, Akira Katoh, Hiroyuki Kouji and Satoshi Gojo

© The Author(s) 2022

In cells, mRNA synthesis and decay are influenced by each other, and their balance is altered by either external or internal cues, resulting in changes in cell dynamics. We previously reported that it is important that an array of mRNAs that shape a phenotype are degraded before cellular transitions, such as cellular reprogramming and differentiation. In adipogenesis, the interaction between DDX6 and 4E-T had a definitive impact on the pathway in the processing body (PB). We screened a library of α-helix analogs with an alkaloid-like backbone to identify compounds that inhibit the binding between DDX6 and 4E-T proteins, which occurs between the α-helix of structured and internally disordered proteins. IAMC-00192 was identified as a lead compound. This compound directly inhibited the interaction between DDX6 and 4E-T. IAMC-00192 inhibited the temporal increase in PB formation that occurs during adipogenesis and epithelial-mesenchymal transition (EMT) and significantly suppressed these cellular transitions. In the EMT model, the half-life of preexisting mRNAs in PBs was extended twofold by the compound. The novel inhibitor of RNA decay not only represents a potentially useful tool to analyze in detail the pathological conditions affected by RNA decay and how it regulates the pathological state. The identification of this inhibitor may lead to the discovery of a first-in-class RNA decay inhibitor drug.

Cell Death Discovery (2022) 8:278; https://doi.org/10.1038/s41420-022-01076-4

INTRODUCTION

Cell fate upon differentiation depends not on only gene expression programs at the transcriptional level but also posttranscriptional processes, such as alternative splicing, polyadenylation, and mechanisms altering mRNA availability, including RNA decay [1]. RNA decay-dependent removal of previous cellular transcripts is a common feature of various cellular transitions, as we have previously reported that reprogramming to induce pluripotent stem cells and adipogenesis requires the eradication of the unique transcriptomes of parent cells [2, 3]. Adipogenesis is a physiological process that produces adipocytes, which are crucial for the body's energy metabolism [4]. In contrast, ectopic adipogenesis occurs in bone [5], heart [6, 7], and skeletal muscle [8], resulting in severe functional impairment. On the other hand, the epithelial-mesenchymal transition (EMT) of cells in solid tumor metastases is an example of a dramatic change in pathogenic phenotype [9]. The ability of mesenchymal cells to acquire the capacity of active and independent migration from their tightly adherent nature to each other as epithelium allows them to form metastases at new sites located away from the primary tumor via the vasculature. Thus, phenotypic turnover is associated with a number of pathological conditions, and RNA decay is considered to be an important mechanism and target for drug discovery.

The elaborate molecular machinery involved in RNA decay has been analyzed in great detail (Fig. 51A). One of the major mRNA decay pathways initiates with the recruitment of the deadenylase complex CCR4-NOT to the 3′ untranslated regions (UTRs) of mRNAs, leading to the displacement of poly(A)-binding protein (PABP), which converts the poly(A) tail to an oligoadenylate form [10] and recruits the RNA decapping machinery [11]. Access to the 5′-terminal cap structure is attributed to 4E-T, one of the decapping machineries, which is bound to eIF4E and CNOT1, constituting CCR4-NOT, resulting in circularization of mRNA targeted for decay [12]. The physical link between CNOT1 and DDX6, a decapping activator, was also reported [13]. DDX6 functions to enhance mRNA decay through decapping [14] and constitutes processing bodies (PBs) along with 4E-T [15]. DDX6 combined with CNOT1 binds to the 4E-T enforcing bridge between the 5′-terminal and 3′-terminal in addition to the interaction of 4E-T and CNOT1 [16]. The interaction between DDX6 and 4E-T is essential for miRNA-dependent translational repression [17]. The spatial and temporal association or dissociation of these effector molecules, such as Ddx6 and 4E-T, enables fine-tuning of the transcriptome to adapt to the environmental and/or genetic cues and to maintain homeostasis in the body.

The molecular machinery of RNA quality control has been analyzed in great detail [18], and numerous proteins are involved in the formation of membraneless organelles, such as PBs and stress granules (SGs) where the fate of mRNA is regulated. Liquid–liquid phase separation (LLPS) is central to its regulation,
and small-molecule compounds that specifically intervene in this mechanism have not yet been developed. Intracellular protein–protein interactions (PPIs), which are typically characterized by large flattened interfaces and hydrophobic interactions, are undruggable to small molecules and effectively inhibit binding between substances by binding concave pockets [19]. Inhibition of PPI by peptides has been proposed as an effective method to address this problem, leading to the development of some effective peptides [20, 21]. According to interactome analysis, approximately 650,000 PPIs are present in cells [22]. Although several strategies to design peptides to inhibit PPIs have been established [19, 23], most of these PPIs have not been modified or inhibited for use in basic research or drug discovery. The problems that needs to be solved for peptide drugs to intervene with PPIs include membrane impermeability and in vivo stability [24]. Although various efforts have been made, such as fusion with cell-penetrating peptides, such as TAT, the results have not yet been sufficient to push peptides into the mainstream of drug discovery [25]. Cyclic peptides that exhibit superior resistance to proteolysis and structural stability compared with linear peptides still have the issue of cell permeability. Although PPIs occur at a wide area of binding surfaces, a limited number of residues have been shown to be involved in the specificity and affinity of their binding and are referred to as hot spots [26]. A common motif found on the binding interface of many PPIs is the α-helix structure with such hot spots [27]. Compounds that mimic this set of planar side chains abrogate α-helix-mediated PPIs [28]. Such fragment-based approaches have been successfully employed to modulate PPIs and generated venetoclax, which was approved by the FDA in 2016 as a first-in-class agent that targets the anti-apoptotic protein Bcl-2 and is clinically used for the treatment of chronic lymphocytic leukemia [29]. Synthetic nonpeptidic small molecules that mimic the structure of a natural α-helix using a template projecting residue with intended arrangements have been intensively investigated [30].

In this study, we investigated whether RNA decay inhibition could inhibit adipogenesis as a physiological process and EMT as a pathological process. The binding of DDX6 and 4E-T, a core component of RNA decay, promotes the decay process by looping single-stranded RNA structures, and we decided to search for small-molecule compounds that inhibit binding at this step. DDX6 and 4E-T are structured and unstructured (intrinsically disordered) proteins, respectively, and a previous report on the interface structure indicated α-helix involvement [16]. We hypothesized that the use of peptidomimetics with cubic scaffolds (PiPiQ) [31] for such a PPI could disrupt the interaction between DDX6 and 4E-T. The development of small-molecule compounds that intervene in the RNA decay process has not been performed to date, and intervention through RNA decay in cellular transitions, including ectopic adipogenesis and cancer metastasis, is considered to have great potential as a new therapeutic target.

**RESULTS**

**Screening for an inhibitor of DDX6 and 4E-T binding**

It has been reported that DDX6 and 4E-T bind directly through RecA2 and the CHD region, respectively, in PBs and are involved in RNA decay [16]. Additionally, knockout of these proteins prevents...
PB formation. We hypothesized that inhibition of the binding of these proteins would also inhibit RNA decay, so we screened for small molecule compounds that inhibit the interaction of these proteins. To screen for such small molecule compounds, two recombinant DNA fragments were designed so that the firefly luciferase enzyme (Fluc) was split into two parts, the N side (Nluc, amino acids 1-416) and the C side (Cluc, amino acids 394-550), each of which would be a protein linked to the RecA2 region of DDX6 and the CHD region of the 4E-T binding fragments, respectively (Fig. S1B). When the two recombinant proteins are introduced into cells and RNA decay is activated, DDX6 and 4E-T bind. Thus, the N- or C-fragment of the enzyme linked to each of the target proteins yields a luciferase protein with enzymatic activity (Fig. 1A).

These fusion genes were loaded onto a forced expression plasmid DNA and transduced into Renilla (Renilla reniformis) luciferase (Rluc)-overexpressing HEK293FT cells, and luciferase activity was observed in the cells using Rluc as an internal control. Either RecA2 of DDX6 or CHD of 4E-T suppressed Fluc activity in genetically modified HEK293FT cells (Fig. S1B). When the two recombinant proteins are introduced into cells and RNA decay is activated, DDX6 and 4E-T bind. Thus, the N- or C-fragment of the enzyme linked to each of the target proteins yields a luciferase protein with enzymatic activity (Fig. 1A).

Inhibition of P-body formation by a small molecular inhibitor

We investigated whether these four compounds, which are less cytotoxic and have been observed to inhibit luciferase activity by inhibiting the binding of DDX6 to 4E-T, inhibit PB formation. A human lung adenocarcinoma cell line, A549, which possesses a significant number of PBs under conventional culture conditions, was forced to express EGFP-DDX6, which is a fusion of the PB marker DDX6 and EGFP, using a retroviral vector. PBs were visualized to observe the effects of the candidate compound in PB formation. The results showed that PBs did not form in the cytoplasm of cells only when treated with #26 (IAMC-00192) [32] (Fig. 2A). DDX6 and 4E-T protein levels in the cells did not change significantly, suggesting that IAMC-00192 did not affect protein expression but rather inhibited PB formation (Fig. 2B, Fig. S2). This compound with a molecular weight of 421.63 and a chemical formula of C_{27}H_{39}N_{3}O is depicted using 3D modeling in Fig. 2C.
Protein–protein interaction analysis

To evaluate the binding of DDX6 to the 4E-T protein and the inhibitory ability of IAMC-00192, we measured PPI by grating-coupled interferometry (GCI) using the WAVE system (Creoptix AG). The proteins required for this WAVE system assay were designed as HA-tagged DDX6 and 4E-T (Fig. 3A), force-expressed in HEK293FT cells and clearly purified by immunoprecipitation using an HA antibody (Fig. 3B, Fig. S3). To calculate the dissociation constant (Kd) between two molecules and the Koff constant rate more specifically, we performed regeneration-free kinetics using the WAVE system (Fig. 3C). First, DDX6 protein was immobilized on the surface of the sensor, and the association and dissociation of 4E-T protein at each concentration were measured continuously from low concentrations. The results showed that the association and dissociation of DDX6 and 4E-T showed values of Kd = 774.3 nM, Kon = 3.59 × 10^2 ± 1.33 × 10^2 M^-1 s^-1, and Koff = 2.78 × 10^-5 s^-1, indicating that these proteins have suitable affinity, relatively gradual association and slow dissociation rate. The same assays were performed in the presence or absence of IAMC-00192 (10 µM) to evaluate its inhibitory ability (Fig. 3D). To correct for the bulk effect of the inhibitor. Of note, the Y-axis was set to all zeros at the start of binding at each concentration during the data process rather than using the prescribed analysis method given the gap in the Y-axis between the association phase and dissociation phase. As a result, clear inhibition of DDX6 and 4E-T protein binding was observed in the presence of the inhibitor (Fig. 3D right) compared to the results obtained with DMSO alone (Fig. 3D left).

Inhibition of Adipogenic Differentiation by Small Molecule Inhibitors

We previously reported that RNA decay in PBs is indispensable for the induction of adipogenic differentiation [2]. When DDX6 and 4E-T were inhibited by RNAi, no PBs were formed. In addition, adipogenic differentiation was arrested, and the remaining transcripts shaped the phenotype of preadipocytes. We examined whether the small molecule inhibitor we identified in this study inhibits PB formation and adipogenesis in the 3T3-L1 adipocyte differentiation system upon treatment with an adipocyte cocktail (AC: insulin, IBMX, and dexamethasone) (Fig. 4A). Before induction, 3T3-L1 cells do not form PBs, which begin to form around Day 4 of adipogenic stimulation [2]. We compared IAMC-00192-treated and -nontreated 3T3-L1 cells and found that IAMC-00192 treatment inhibited PB formation (Fig. 4B). On the other hand, no differences in DDX6 and 4E-T protein levels were noted in these cells (Fig. 4C, Fig. S2). These results suggest that IAMC-00192 inhibits PB formation in a physiological setting without affecting DDX6 and 4E-T protein expression, and similar results were obtained in A549 cells. After 8 days of induction of adipogenic differentiation, almost no lipid droplets were observed in the experimental group treated with IAMC-00192 (Fig. 4D). On the other hand, the control group showed differentiation into adipocytes with many lipid droplets that showed strong positivity as assessed by Oil Red O (ORO) staining (Fig. S4). Gene expression of adipogenic differentiation-related factors and EMT was analyzed (Fig. 4E). Cebpa and Fabp4 levels were lower in the cells treated with IAMC-00192 at all time points. Cebpb and Cebpd, which are transiently expressed in the early stage of adipogenic differentiation, were maintained in IAMC-00192. Reduced Pparg expression was noted in cells treated with IAMC-00192 alone for 8 days. Next, we evaluated factors associated with EMT that change with adipogenic differentiation and found that Zeb1, Snai1, and Twist1 genes were all highly elevated from Day 3 to Day 8 in cells treated with IAMC-00192, indicating that several key transcripts for adipogenesis were maintained even after the external cue. These results suggest that the inhibitor of DDX6 and the 4E-T interaction can modulate RNA decay and intervene in adipogenesis.

RNA analysis in P-bodies

Endogenous RNA decay is expected to be important not only in the induction of adipogenic differentiation but also in cellular transitions, such as EMT. Therefore, we evaluated the effect of
IAMC-00192 on EMT using A549 cells, a model for cellular transitions. We evaluated the RNA molecules contained in the PBs of A549 cells during the EMT process. To evaluate how inhibition of PB formation affects cellular transitions in pathophysiological conditions, we analyzed RNA molecules contained in PBs using the RNA-seq method [33]. First, EGFP-DDX6 was force-expressed in A549 cells to establish cells in which PB fluoresces with EGFP. Using these cells, RNA was collected before and after EMT with TGFB2 (Tb2) (CNT and Tb2) from the cytoplasm and PBs (Cyto and PB) (Fig. 5A). PBs were collected by FACS (Fig. 5B). The collected RNAs were analyzed by next-generation sequencing. The quality of the collected RNA was assessed, and it was found that the PB fraction contained fewer short RNA molecules than the cytoplasm (Fig. 5C). Given the lack of a common internal standard factor in this analysis, it was difficult to compare the expression levels among samples. Therefore, we decided to identify the genes that showed higher expression levels than the average expression level of each sample and analyze the common gene groups. In total, 3124 genes in CNT Cyto, 3227 genes in CNT PB, 2733 genes in Tb2 Cyto, and 1867 genes in Tb2 PB showed higher than average values (Fig. 5D). Next, there were 875 genes specific for PBs in CNTs and 309 genes specific for Tb2 (Fig. 5E).

Epithelial-mesenchymal transition inhibition by small-molecule inhibitors

IAMC-00192 inhibited the induction of adipogenic differentiation associated with EMT suppression through the suppression of RNA decay. Therefore, we evaluated IAMC-00192 using A549 and Tb2 cells, which are model cells for EMT. EMT-induced A549 cells form intracellular F-actin, which reacts with phalloidin. IAMC-00192 inhibited the formation of intracellular F-actin and drastically reduced the amount of reaction (Fig. 6A, B, Fig. S5), indicating significant suppression of EMT. These results showed that the phenotype emerged on Day 2. We thought that RNA degradation should be evaluated at an earlier stage, so we evaluated RNA degradation in the early stage (0-24 hr) of Tb2 stimulation with actinomycin D (ActD). The results showed that IAMC-00192
enhanced the stability of the ELF3 gene and increased the RNA half-life 2.1-fold during this period (Fig. 6C). On the other hand, no significant changes in the GAPDH and CDH1 genes were noted. In the EMT model, the compounds we found also suppressed RNA decay, resulting in a preexisting transcriptome, which subsequently inhibited the expression of the transcriptome characteristic of the new mesenchymal phenotype. This finding is similar to the inhibition of transcriptome expression in parental cells leading to the suppression of differentiation to mature adipocytes in adipogenesis. In both physiological and pathological processes, cellular transitions were suppressed by our compound to inhibit the RNA decay core machinery.

**DISCUSSION**

In the present study, we selected small molecule compounds that inhibit the association of DDX6 and 4E-T using the strategy of peptidomimetics and found that the compounds suppressed the elimination of transcripts encoding proteins constituting the preexisting phenotype in adipogenic differentiation and EMT of cancer cells. Additionally, PBs, membraneless organelles in the cytoplasm that are thought to be the site of RNA decay, were also reduced. Thus, differentiation induction could not occur. The lead compound in this study inhibited the binding of DDX6 and 4E-T in a concentration-dependent manner in the PPI in vitro, representing a first-in-class compound that modifies or inhibits PPI in RNA decay machinery. This study demonstrates that α-helix mimetics using PiPiQ can effectively inhibit intracellular PPI for RNA decay.

The design of peptidomimetics can be broadly classified into four categories [23]. The first categories involves the amino acid sequence of the target peptide, and the second is the peptide that is modified in various ways, including the backbone and amino acid residues. Third, the backbone is completely replaced by a small molecule, and several substitutes are projected from the scaffold to mimic the arrangement of amino acid residues in the hot spot. Finally, the compound mimics the mode of action of binding to a ligand that is not directly related to the hot spot. Methodologies to generate mimetics for various secondary structures, such as β-sheets and α-helices, have been intensively investigated. In this study, we adopt the third category for peptidomimetics, replacing the backbone with curbed alkaloid-like small molecule compounds, mimicking the spatial orientation of the R, R+3, and R+4 amino acid residues of the target peptide and projecting from its scaffold to a single surface of a PPI, named PiPiQ [31]. With respect to the properties of proteins, PPIs can be classified into domain-domain and peptide-domain
interfaces. The latter has a unique secondary structure in the corresponding peptide, typically an α-helix structure, which is intrinsically disordered [34] and makes extensive use of several motifs, such as LxxLL [35] and FxxFF [36]. The three amino acid residues in PiPiQ were selected based on these motifs, and a library of 200 compounds was constructed for the screening performed this study. The three-dimensional structures of the DDX6 and 4E-T proteins themselves and their binding surfaces have been analyzed and are predicted to form the helix of the disordered protein 4E-T. In the attempt to create an inhibitor for PPI, designing a peptidomimetic that mimics the hot spots from the reported 3D structure is an obviously time-consuming task. To circumvent this step, we fused a split luciferase with each protein fragment [39] and performed the first screening to search for the inhibitor. This method is unique in that it does not require direct fluorescent labeling, antibodies, or beads and can be performed exclusively using conventional molecular biological recombination techniques. Many methods have been reported to quantitatively measure the kinetics and affinity of PPI and the efficacy of inhibitors, such as SPR [40] and isothermal calorimetry [41]. The application of SPR to PPI is based on the fact that a protein/peptide/fragment, which forms the interest of PPI, is solidified on a gold chip and excited by polarized light, causes collective oscillations and measures SPR reflectance. Technically, using a microfluidic system, changes in the SPR signal can be detected by injecting and washing out the corresponding proteins relative to the solidified proteins, and the binding constants can be derived from the association and dissociation rates [42]. The system can be used as a competitive assay by introducing a putative inhibitor into this channel [43]. In this experiment, the grating coupled acoustic wave was used to calculate the coupling constants of DDX6 and 4E-T [44], and the effectiveness of inhibition by IAMC-00192 was also confirmed. The advantage of this system is that the amount of protein required is the same as that used for expression experiments at the conventional laboratory level. Additionally, Biacore, which is based on the SPR principle, was not sensitive enough to measure this PPI in this study, suggesting that the appropriate measurement method may differ depending on the nature of the target protein.

The effective in vitro IAMC-00192 concentration discovered in this study is 10 μM, and it is still a lead compound that needs to be optimized. Using this compound as a foothold, we will need to establish its efficacy at subμM concentrations and investigate its off-target and precise allosteric effects. In addition, it is necessary to reproduce the in vitro effects in vivo as a step toward clinical use. In the postgenomic era, post-transcriptional modifications have also been shown to be involved in a wide variety of biological reactions, but the development of compounds to modify these processes has not progressed as expected. The discovery of compounds that inhibit RNA decay, which is one of the intracellular PPIs and is regulated by and involved in a large...
number of proteins through LLPS, opens up the possibility of developing various drugs that target RNA decay and provides a strategy for targeting EMT and ectopic adipogenesis. This is particularly important given the lack of treatments is currently available to treat these conditions.

MATERIALS AND METHODS

Drug screening using luciferase activity

HER293FT HUVEC cells (5 x10^4 per well) seeded with Niuc-DDX6 and Cluc_4E-T plasmid (20 ng per well) and Lipofectamine 3000 (Thermo Fisher Scientific Incorporated) in White/96-well Clear Flat Bottom TC-treated Culture MicroPlate (Corning Incorporated. Corning, New York, US). Briefly, the plasmid and lipofectamine 3000 reacted in Opti-MEM for 10 min at room temperature, mixed with trypsin-treated cells, and seeded onto 96-well plates. Eighteen hours after seeding, the cells were incubated for 48 h with exposure to the small molecule compound. Eighteen hours after seeding, the cells were further incubated with small molecular inhibitors, and 48 h later, these cells were assayed for luciferase levels using the Dual-luciferase reporter assay system (Promega Corporation) and Teco F200 plate reader (Tecan Group Ltd. Männedorf, Switzerland) was used for measurement.

Protein-protein interaction analysis by WAVESystem

For mRNA half-life measurements, transcription was blocked by actinomycin D (2.5 µg/ml) and the cells were harvested at the indicated time points using TRIzol reagent and Direct-zol RNA Miniprep Kits. Determine the mRNA decay rate by nonlinear regression curve fitting (one phase decay) using GraphPad Prism (Prism 8.4.3 software, GraphPad Prism Software Incorporated, San Diego, CA, USA [45]).

Statistical analysis

The results are expressed as the means ± Standard Deviation (SD). The statistical significance of differences among groups was evaluated using parametric unpaired t-tests for bar graphs using GraphPad Prism. P < 0.05 was considered to indicate significance.

DATA AVAILABILITY

The present study's data are available from the corresponding author upon reasonable request.

REFERENCES

1. Rabani M, Raychowdhury R, Jovanovic M, Rooney M, Stumpo DJ, Pauli A, et al. High-resolution sequencing and modeling identifies distinct dynamic RNA reg-ulatory strategies. Cell. 2014;159:698–710.

2. Maeda R, Kami D, Shikuma A, Suzuki Y, Taya T, Motaba S, et al. RNA decay in processing bodies is dispensable for adipogenesis. Cell Death Dis. 2011;2:285.

3. Kami D, Kiti T, Nakamura A, Waku N, Mizutani R, Ohue M, et al. The DEAD-box RNA-binding protein DDX6 regulates parental RNA decay for cellular reprogram-   ming to pluripotency. PLoS One. 2018;13:e0203708.

4. Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol. 2011;12:722–34.

5. Ambroz TH, Scalidone A, Gnaa A, Gohike S, Jank AM, Bocian C, et al. Adsope Accumulation in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and Bone Regeneration. Cell Stem Cell. 2017;20:771–784 e776.

6. Pouliopoulos J, Chik WW, Kanthan A, Sivagangabalan G, Barry MA, Fahmy PN, et al. Intramyocardial Adiposity Post-Myocardial Infarction: New Implications of a Substrate for Ventricular Tachycardia. Circulation. 2013;128:2296–308.

7. van der Voom SM, Te Riele A, Basso C, Calkins H, Remme CA, van Veen TAB. Arrhythmogenic cardiomyopathy: pathogenesis, pro-arrhythmic remodelling, and novel approaches for risk stratification and therapy. Cardiovasc Res. 2020;116:1571–84.

8. Kopinke D, Roberson EC, Reiter JF, Ciliary Hedgehog Signaling Restricts Injury-Induced Adipogenesis. Cell. 2017;170:340–351 e312.

9. Passtushenko I, Blapain C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2019;29:212–26.

10. Zekri I, Kuzugolu-Ozturk D, Izaurralde E. GW182 proteins cause PABP dissociation from silenced miRNA targets in the absence of deadenylation. EMBO J. 2013;32:1052–65.

11. Chowdhury A, Thanu S. Activation of decapping involves binding of the mRNA and facilitation of the post-binding steps by the Lsm1-7-Pat1 complex. RNA. 2009;15:1837–48.

12. Nishimura T, Padamzi M, Fakim H, Milette S, Dunham WH, Gingras AC, et al. The elf4E-Binding Protein 4E-T Is a Component of the mRNA Decay Machinery that Bridges the 5′ and 3′ Terminals of Target mRNAs. Cell Rep. 2015;11:1425–36.

13. Mathys H, Basquin J, Ozgur S, Czarnocki-Cieciura M, Bonnaud F, Aartse A, et al. Structural and biochemical insights to the role of the CCR4-NOT complex and DDX6 ATPase in microRNA repression. Mol Cell. 2014;54:751–65.

14. Colmer JM, Tucker M, Sheth U, Valencia-Sanchez MA, Parker R. The DEAD box helicase, Dih1p, functions in mRNA decay and interacts with both the decapping and deadenylylase complexes. Rna. 2001;7:1717–27.

15. Anderson P, Redershia N. RNA granules. J Cell Biol. 2006;172:803–8.

16. Ozgur S, Basquin J, Kamenska A, Filipovicz W, Standart N, Conti E. Structure of a Human 4E-T/DDX6/CNOT1 Complex Reveals the Different Interplay of DDX6- Binding Proteins with the CCR4-NOT Complex. Cell Rep. 2015;13:703–11.

17. Kamenska A, Simpson C, Vindy C, Broomhead H, Benard M, Erollt-Lange M, et al. The DDX6-4E-T interaction mediates translational repression and P-body assembly. Nucleic Acids Res. 2016;44:3138–41.

18. Labno A, Tomecki R, Dziembowski A. Cytoplasmic RNA decay pathways - Enzymes and mechanisms. Biochim Biophys Acta. 2016;1863:3125–47.

19. Cunningham AD, Qvit N, Mochly-Rosen D. Peptides and peptidomimetics as regulators of protein-protein interactions. Curr Opin Struct Biol. 2017;44:59–66.

20. Qvit N, Diatniak M-H, Sho E, Mochly-Rosen D. Selective Phosphorylation Inhibitor of Delta Protein Kinase C-Pyruvate Dehydrogenase Kinase Protein-Protein Interactions: Application for Myocardial Injury in Vivo. J Am Chem Soc. 2016;138:7626–35.

21. Qi X, Qvit N, Su Y-C, Mochly-Rosen D. A novel Dpl inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci. 2013;126:789–802.

22. Stumpf MP, Thorne T, de Silva E, Stewart R, An HJ, Lappe M, et al. Estimating the size of the human interactome. Proc Natl Acad Sci USA. 2008;105:6959–64.

23. Pelay-Gimeno M, Glas A, Koch O, Grossmann TN. Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes. Angew Chem Int Ed Engl. 2015;54:8896–927.

24. Lee AC, Harris JL, Khanna KK, Hong JH. A Comprehensive Review on Current Advances in Peptide Drug Development and Design. Int J Mol Sci. 2019;20:2383.

25. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current develop-   ment trends, and future directions. Bioorg Med Chem. 2016;26:2700–7.

26. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor protein interactions using designed molecules. Nat Chem. 2013;5:161.

27. Edwards TA, Wilson AJ. Helix-mediated protein–protein interactions as targets for intervention using foldamers. Amino Acids. 2011;41:743–54.

28. Azzarito V, Long K, Murphy NS, Wilson AJ. Inhibition of alpha-helix-mediated protein-protein interactions using designed molecules. Nat Chem. 2013;5:161–73.

29. Valenti D, Hristeva S, Tzalis D, Oettmann C. Clinical candidates modulating protein-protein interactions: The fragment-based experience. Eur J Med Chem. 2019;167:76–95.

30. Algar S, Martin-Martinez M, Gonzalez-Muniz R. Evolution in non-peptide alpha-helix mimetics on the road to effective protein-protein interaction modulators. Eur J Med Chem. 2021;211:13015.

31. Shimizu T, Takahashi N, Huber VJ, Asawa Y, Ueda H, Yoshimori A, et al. Design and synthesis of 14 and 15-membered macrocyclic scaffolds exhibiting inhibi-   tory activities of hypoxia-inducible factor 1alpha. Bioorg Med Chem. 2021;30:115949.

32. Koju H, 3.6-Methan-1-H-Pyrrol(3,2-b)Pyridine and 3.6-Methan-1-H-Pyrrol(3,2-c)Pyridine compounds and medications using same. USA patent US 17/679,075 (2018).

33. Hubstenberger A, Courel M, Bénard M, Souquere S, Enrollt-Lange M, Chouaib R, et al. P-Body Purification Reveals the Condensation of Regressed mRNA Regulons. Mol Cell. 2017;68:144–157.e145.

34. Nevola L, Giralt E. Modulating protein-protein interactions: the potential of peptides. Chem Commun (Camb). 2015;51:3302–15.

35. Plevin MJ, Mills MM, Ikura M, The LooXLM motif: a multifunctional binding sequence in transcriptional regulation. Trends Biochem Sci. 2005;30:56–69.
36. van de Wijngaart DJ, van Royen ME, Hersmus R, Pike AC, Houtsman AB, Jenster G, et al. Novel FXXFF and FXXMF motifs in androgen receptor cofactors mediate high affinity and specific interactions with the ligand-binding domain. J Biol Chem. 2006;281:19407–16.

37. Lodge JM, Rettenmaier TJ, Wells JA, Pomerantz WC, Mapp AK. FP tethering: a screening technique to rapidly identify compounds that disrupt protein–protein interactions. MedChemComm. 2014;5:370–5.

38. Schaap M, Hancock R, Wilderspin A, Wells G. Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction. Protein Sci. 2013;22:1812–9.

39. Kim HK, Cho EJ, Jo S, Sung BR, Lee S, Yun SH. A split luciferase complementation assay for studying in vivo protein-protein interactions in filamentous ascomycetes. Curr Genet. 2012;58:179–89.

40. Douzi B. Protein-Protein Interactions: Surface Plasmon Resonance. Methods Mol Biol. 2017;1615:257–75.

41. Ramirez J, Nomine Y. High-Quality Data of Protein/Peptide Interaction by Isothermal Titration Calorimetry. Methods Mol Biol. 2019;1964:99–117.

42. Leth JM, Ploug M. Determination of Binding Kinetics of Intrinsically Disordered Proteins by Surface Plasmon Resonance. Methods Mol Biol. 2020;2141:611–27.

43. Choulier L, Nominé Y, Zeder-Lutz G, Charbonnier S, Didier B, Jung M-L, et al. Chemical library screening using a SPR-based inhibition in solution assay: simulations and experimental validation. Anal Chem. 2013;85:8787–95.

44. Patko D, Cottier K, Hamori A, Horvath R. Single beam grating coupled interferometry: high resolution miniaturized label-free sensor for plate based parallel screening. Opt Express. 2012;20:23162–73.

45. Ratnadiwakara M, Anko M-L. mRNA Stability Assay Using Transcription Inhibition by Actinomycin D in Mouse Pluripotent Stem Cells. BIO-PROTOCOL 2018;8:3072.

ACKNOWLEDGEMENTS

We thank Mr. Takeshi Seguchi and Mr. Takuya Saito of Primetech Corporation for their great help in the analysis of the WAVE system. We also thanks to Ms. Sayuri Shikata for her technical assistance. This work was supported by JSPS KAKENHI Grant Number 18K06065.

AUTHOR CONTRIBUTIONS

SG designed the research and analyzed the data; DK performed all experiments; DK and SG wrote the paper; TI, AK, and HK reviewed and provided suggestions on the experiments and the manuscript. AK and HK synthesized the all compounds.